ProfileGDS4814 / ILMN_1751753
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 87% 87% 86% 86% 87% 87% 86% 87% 87% 86% 87% 88% 84% 86% 87% 86% 87% 86% 90% 88% 88% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)282.20287
GSM780708Untreated after 4 days (C2_1)291.70387
GSM780709Untreated after 4 days (C3_1)268.18786
GSM780719Untreated after 4 days (C1_2)268.97786
GSM780720Untreated after 4 days (C2_2)299.07687
GSM780721Untreated after 4 days (C3_2)277.37387
GSM780710Trastuzumab treated after 4 days (T1_1)270.59286
GSM780711Trastuzumab treated after 4 days (T2_1)278.51687
GSM780712Trastuzumab treated after 4 days (T3_1)286.2187
GSM780722Trastuzumab treated after 4 days (T1_2)265.69586
GSM780723Trastuzumab treated after 4 days (T2_2)279.69487
GSM780724Trastuzumab treated after 4 days (T3_2)314.46188
GSM780713Pertuzumab treated after 4 days (P1_1)209.72884
GSM780714Pertuzumab treated after 4 days (P2_1)265.00286
GSM780715Pertuzumab treated after 4 days (P3_1)275.02687
GSM780725Pertuzumab treated after 4 days (P1_2)243.70486
GSM780726Pertuzumab treated after 4 days (P2_2)293.9687
GSM780727Pertuzumab treated after 4 days (P3_2)248.23486
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)411.28190
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)324.57388
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)310.35388
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)332.71988
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)327.55688